Vitae Pharmaceuticals Inc. (NASDAQ:VTAE)’s share price fell 1.4% during trading on Tuesday . The company traded as low as $10.44 and last traded at $10.46, with a volume of 200,625 shares. The stock had previously closed at $10.61.

A number of brokerages have commented on VTAE. Wells Fargo & Co. reiterated a “buy” rating on shares of Vitae Pharmaceuticals in a report on Friday, June 10th. Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Vitae Pharmaceuticals in a report on Wednesday, May 25th. Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.25 target price for the company in a report on Thursday, May 5th. BMO Capital Markets assumed coverage on shares of Vitae Pharmaceuticals in a report on Monday, April 11th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Vitae Pharmaceuticals in a report on Sunday, March 20th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Vitae Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $16.65.

The firm has a 50-day moving average of $10.32 and a 200 day moving average of $9.17. The firm’s market cap is $301.68 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. The business had revenue of $0.05 million for the quarter. Vitae Pharmaceuticals’s revenue for the quarter was down 66.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.47) earnings per share. Analysts expect that Vitae Pharmaceuticals Inc. will post ($1.74) earnings per share for the current year.

A hedge fund recently bought a new stake in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP acquired a new position in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned about 0.34% of Vitae Pharmaceuticals as of its most recent SEC filing.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.